Suggestions

Du même auteur

Is CAR T a Drug or a Therapeutic Pathway? Systematic Review, (Re-)Estimation of Efficacy Endpoints and Metanalyses in Large B-Cell Lymphoma Real World Reports

Archive ouverte | Zinzani, Pier Luigi | CCSD

International audience

Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment

Archive ouverte | Iacoboni, Gloria | CCSD

International audience

Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

Archive ouverte | Rejeski, Kai | CCSD

International audience. Hematological toxicity is the most common adverse event after chimeric antigen receptor (CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for severe infecti...

Chargement des enrichissements...